In elderly patients, the hospitalization rate for infections with vedolizumab or ustekinumab is lower than with anti-TNF, and the overall adverse event rates are similar [338, 339]; Organ transplant recipients using biologics must be cautious of severe infections, but no significant difference in tumor risk has been observed [340, 341]. Here, TNF is linked to neoplasm.